Logo image of LPTX

LEAP THERAPEUTICS INC (LPTX) Stock Fundamental Analysis

NASDAQ:LPTX - Nasdaq - US52187K2006 - Common Stock - Currency: USD

0.3923  -0.02 (-4.29%)

After market: 0.4089 +0.02 (+4.23%)

Fundamental Rating

2

LPTX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. LPTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LPTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LPTX has reported negative net income.
In the past year LPTX has reported a negative cash flow from operations.
LPTX had negative earnings in each of the past 5 years.
LPTX had a negative operating cash flow in each of the past 5 years.
LPTX Yearly Net Income VS EBIT VS OCF VS FCFLPTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

With a Return On Assets value of -198.99%, LPTX is not doing good in the industry: 89.23% of the companies in the same industry are doing better.
LPTX has a Return On Equity of -333.03%. This is in the lower half of the industry: LPTX underperforms 74.15% of its industry peers.
Industry RankSector Rank
ROA -198.99%
ROE -333.03%
ROIC N/A
ROA(3y)-109.13%
ROA(5y)-86.19%
ROE(3y)-140.51%
ROE(5y)-107.95%
ROIC(3y)N/A
ROIC(5y)N/A
LPTX Yearly ROA, ROE, ROICLPTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LPTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LPTX Yearly Profit, Operating, Gross MarginsLPTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K -2.5K

More info and screens

5

2. Health

2.1 Basic Checks

LPTX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for LPTX has been increased compared to 5 years ago.
There is no outstanding debt for LPTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LPTX Yearly Shares OutstandingLPTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
LPTX Yearly Total Debt VS Total AssetsLPTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

LPTX has an Altman-Z score of -24.73. This is a bad value and indicates that LPTX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of LPTX (-24.73) is worse than 87.43% of its industry peers.
There is no outstanding debt for LPTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -24.73
ROIC/WACCN/A
WACCN/A
LPTX Yearly LT Debt VS Equity VS FCFLPTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 2.41 indicates that LPTX has no problem at all paying its short term obligations.
The Current ratio of LPTX (2.41) is worse than 70.74% of its industry peers.
A Quick Ratio of 2.41 indicates that LPTX has no problem at all paying its short term obligations.
With a Quick ratio value of 2.41, LPTX is not doing good in the industry: 69.12% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.41
Quick Ratio 2.41
LPTX Yearly Current Assets VS Current LiabilitesLPTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

LPTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.87%, which is quite impressive.
EPS 1Y (TTM)28.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, LPTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.37% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y38.47%
EPS Next 2Y30.62%
EPS Next 3Y19.23%
EPS Next 5Y13.37%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LPTX Yearly Revenue VS EstimatesLPTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2029 2030 2031 2032 50M 100M 150M
LPTX Yearly EPS VS EstimatesLPTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LPTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LPTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LPTX Price Earnings VS Forward Price EarningsLPTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LPTX Per share dataLPTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as LPTX's earnings are expected to grow with 19.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.62%
EPS Next 3Y19.23%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LPTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEAP THERAPEUTICS INC

NASDAQ:LPTX (6/16/2025, 8:00:00 PM)

After market: 0.4089 +0.02 (+4.23%)

0.3923

-0.02 (-4.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners42.03%
Inst Owner Change-17.46%
Ins Owners0.58%
Ins Owner Change0.66%
Market Cap16.26M
Analysts43.33
Price Target3.06 (680.02%)
Short Float %4.73%
Short Ratio0.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.89%
Min EPS beat(2)-0.76%
Max EPS beat(2)4.54%
EPS beat(4)2
Avg EPS beat(4)-1.16%
Min EPS beat(4)-18.56%
Max EPS beat(4)10.13%
EPS beat(8)6
Avg EPS beat(8)5.23%
EPS beat(12)7
Avg EPS beat(12)-18.9%
EPS beat(16)10
Avg EPS beat(16)-13.8%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)17.14%
EPS NY rev (1m)0%
EPS NY rev (3m)12.14%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.78
P/tB 0.78
EV/EBITDA N/A
EPS(TTM)-1.7
EYN/A
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)-1.43
FCFYN/A
OCF(TTM)-1.43
OCFYN/A
SpS0
BVpS0.5
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -198.99%
ROE -333.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-109.13%
ROA(5y)-86.19%
ROE(3y)-140.51%
ROE(5y)-107.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.41
Quick Ratio 2.41
Altman-Z -24.73
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.45%
EPS Next Y38.47%
EPS Next 2Y30.62%
EPS Next 3Y19.23%
EPS Next 5Y13.37%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-20.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-17.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.99%
OCF growth 3YN/A
OCF growth 5YN/A